Chiesi Limited headquartered in Manchester, employs over 400 people. Based in Parma, Italy, Chiesi Farmaceutici is an international research-focused group with over 85 years’ experience in the pharmaceutical sector operating in 30 countries, employing around 6,000 people. Chiesi’s Parma based Research and Development Centre coordinates the activities of six other centres in France, U.S.A, Canada, China, UK, and Sweden to promote its pre-clinical, clinical, and regulatory programmes. To achieve its mission of improving people’s quality of life by acting responsibly towards society and the environment, Chiesi researches, develops and markets drugs in its three therapeutic areas: AIR (respiration, new-born to adult populations), RARE (rare and ultra-rare diseases) and CARE (special care and consumer-facing self-care). Chiesi, since 2019, is the world’s largest B Corp certified pharmaceutical group. The global B Corp movement promotes business as a force for good. The Group is committed to becoming carbon neutral by the end of 2035.
Click here to contact us by email
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
AstraZeneca is based in six different locations across the UK, with its global headquarters in Cambridge. In the UK, almost 8,000 employees work in research and development, manufacturing, supply, sales and marketing. We supply 34 different medicines to the NHS, which treat more than one million UK patients every year.
For more information, please visit www.astrazeneca.co.uk and follow us on Twitter @AstraZenecaUK
CliniMed offers a unique range of skin care products that are cost effective without compromising on quality. Appeel® Sterile Medical Adhesive Remover helps to prevent medical adhesive-related skin injury (MARSI) and pain by facilitating the quick and easy removal of dressings and other adhesive appliances from the skin. Appeel® Sterile is currently the only sterile silicone-based adhesive remover suitable for use on intact and injured skin and is highly recommended for high-risk patients including those with open wounds, intravenous access sites, central lines, percutaneous endoscopic gastrostomy (PEGs), and those who are immunocompromised. The skin care range also includes LBF® Sterile Barrier Film and LBF® Barrier Cream which protect the skin from the harmful effects of bodily fluids, as well as from friction, shear, and adhesive trauma. Also includes CliniSorb®, an odour control dressing to improve patient quality of life.
If you require further information, a team training session or if you would like to speak to a member of the team, please email us at: firstname.lastname@example.org or call us on 0808 1596 017
Tillotts are specialists in gastrointestinal health (GI) with over 30 years’ experience developing and manufacturing treatments for inflammatory bowel disease. Tillotts now have over 2 million patient years’ experience in the treatment of ulcerative colitis. With a development pipeline of new and innovative medicines for patients with diseases of the digestive system Tillotts are passionate about GI.
Tillotts are also passionate about supporting health care professionals who care for GI patients in order to help improve patient care. Tillotts’ LOGIC Education programme offers training and support, and our annual Richard Driscoll award encourages best practice sharing and recognises the achievements of IBD Nurses.
Tillotts are proud to support and sponsor the IBD Registry and Crohn’s & Colitis UK.
Tillotts are part of the Zeria Group.